[Antiphospholipid activity of the blood in patients with ischemic heart disease and thrombogenic complications]

Related Experiment Video

Updated: Jul 24, 2026

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

L V Shashilina, S A Urazgil'deeva, M M Mnuskina

    Klinicheskaia Meditsina
    |February 20, 2004
    PubMed

    Insights

    This study introduces a new method to detect antiphospholipid activity using phospholipid (PL) assays in circulating immune complexes (CIC). This screening aids in diagnosing conditions like antiphospholipid syndrome in patients with heart disease.

    Area of Science:

    • Immunology
    • Cardiology
    • Clinical Chemistry

    Context:

    • Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disorder.
    • Ischemic heart disease (IHD) can be associated with thrombotic complications.
    • Current diagnostic methods for APS may require further refinement.

    Purpose:

    • To propose a novel method for estimating antiphospholipid activity.
    • To evaluate the utility of phospholipid (PL) assays in circulating immune complexes (CIC) for diagnostic purposes.
    • To establish PL screening in CIC as an additional diagnostic test.

    Summary:

    • The study details a method for assessing blood antiphospholipid activity by performing phospholipid (PL) assays within circulating immune complexes (CIC).
    • This approach involves the detection and quantification of phospholipids involved in immune complex formation.
    • The methodology aims to provide a more targeted assessment of antiphospholipid antibodies.

    Impact:

    • This method can serve as an additional diagnostic tool for patients with suspected antiphospholipid syndrome (APS).
    • It offers a potential adjunctive screening test for patients experiencing thrombotic complications related to ischemic heart disease (IHD).
    • Improved diagnostic capabilities may lead to earlier intervention and better patient outcomes in managing thrombotic risks.

    More Related Videos

    Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)04:56

    Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

    Published on: August 4, 2023

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

    Published on: February 27, 2026

    Related Concept Videos

    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
    Peripheral Artery Disease I: Introduction01:30

    Peripheral Artery Disease I: Introduction

    Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...